Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis

BACKGROUND: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). But relapse and refractory DLBCL occur frequently. Although ritu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yuan-Rong, Jin, Yong-Dong, Zhang, Zhi-Hui, Li, Li, Wu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837870/
https://www.ncbi.nlm.nih.gov/pubmed/25635435
http://dx.doi.org/10.4103/0366-6999.150111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837870/
https://www.ncbi.nlm.nih.gov/pubmed/25635435
http://dx.doi.org/10.4103/0366-6999.150111

Ejemplares similares